aTyr Pharma Stock News

SAN DIEGO, April 01, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its pro

When it comes to deciding whether you should acquire penny stocks or not, the answer is no. Okay, so we're done here, right?

aTyr Pharma, Inc. (LIFE) Q4 2023 Earnings Call Transcript

SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its prop

Penny stocks will always provide us with investment opportunities in the event that we do not have a completely high buying power and do not want to buy fractional shares. In the large ecosystem of co

SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its prop

These top-ranked stocks are likely to beat on the bottom line in their upcoming releases. Tap American Woodmark (AMWD), Skechers (SKX), Workday (WDAY), aTyr Pharma (LIFE) and Modine Manufacturing (MOD

Atyr Pharma (LIFE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revisi

SAN DIEGO, Aug. 24, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA

Top-ranked stocks Yum China (YUMC), Amazon.com (AMZN), Workday (WDAY), aTyr Pharma (LIFE) and D.R. Horton (DHI) are likely to beat on the bottom line in their upcoming releases.

Atyr Pharma (LIFE) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.44 per share a year ago.

This year's rally has seen many growth stocks deliver triple-digit returns, especially ones from the AI sector. Investors are willing to take more risks in 2023, and growth names have strongly trended

Presentations highlight efzofitimod's novel myeloid-cell focused mechanism and current Phase 3 EFZO-FIT ™ study in pulmonary sarcoidosis .

SAN DIEGO, May 25, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA s

SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA s